Geminiguy - Would appreciate your thoughts
You said -
"In my opinion (and according to others in the field), a year from now, not only will Immunaid be the golden egg for GTG/GENE, it will be worth more than the total market cap of Genetic Technologies in its own right."
And then in your last post said -
"They had nothing...now they have a holding worth 4.6m"
So if as you say in a year from now that Immunaid will be the golden egg why would GTG dilute their holding in the company from 70% to 46%?
I had a look at the patents pending and granted for Immunaid on the EPO website and it looked to me that with patents being granted and as you said future upside over the next 12 months why as major shareholder would you take such a dilution if you knew as you have said that further raisings would be done a much higher prices?
I am just having a look at this company and when there are subsidiary companies there are a lot of layers to look into when choosing to invest in the parent company.
With the share of Immunaid reducing greatly investment in GTG needs to be based on future projections for Brevagen sales and patent licensing agreements.
Did I see in a Brevagen video (cant find the link) that the Brevagen test is currently only for Anglosaxon women?
Would be interested to hear thoughts on expected revenue growth for the Brevagen test over the next 12 months
Thanks
Twinvest
- Forums
- ASX - By Stock
- GTG
- future profitability
future profitability, page-20
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
CC9
Chariot Corporation (ASX:CC9) refines Black Mountain strategy, launching Pilot Mine to seize U.S. lithium opportunity
LU7
Discover the strong preliminary feasibility of the Bécancour Lithium Refinery, showcasing resilience in a low pricing environment and a strategic plan to capitalize on future price recoveries
Add GTG (ASX) to my watchlist
(20min delay)
|
|||||
Last
4.0¢ |
Change
-0.003(6.98%) |
Mkt cap ! $5.816M |
Open | High | Low | Value | Volume |
4.3¢ | 4.3¢ | 4.0¢ | $51 | 1.196K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 50438 | 4.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
4.3¢ | 42133 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 50223 | 0.040 |
4 | 171524 | 0.039 |
6 | 445749 | 0.038 |
6 | 91062 | 0.037 |
3 | 54887 | 0.036 |
Price($) | Vol. | No. |
---|---|---|
0.043 | 42133 | 2 |
0.045 | 22522 | 1 |
0.046 | 40000 | 1 |
0.049 | 2414 | 1 |
0.050 | 25556 | 2 |
Last trade - 15.37pm 04/10/2024 (20 minute delay) ? |
Featured News
GTG (ASX) Chart |